US FDA Approves Pritelivir for Refractory Herpes Infections

The US Food and Drug Administration (FDA) has approved pritelivir (Hovilpri, Asahi Kasei Therapeutics, Inc.) tablets for immunocompromised adults with mucocutaneous lesions caused by herpes simplex virus (HSV) infection who have not responded to treatment with acyclovir, valacyclovir, or famciclovir.